LCL161 clinical trials
Also written LCL161.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses LCL161 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 3
Novartis Pharmaceuticals (6) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · SCRI Development Innovations, LLC (1) · US Oncology Research (1)
Often tested with
Tested in the same studies.
Spartalizumab (2) · CXCR2 Antagonist QBM076 (1) · Siremadlin (1) · CJM-112 (1)
Studies
Open first, then newest update. How each study uses LCL161 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesTerminatedPhase 1SCRI Development Innovations, LLCNCT02649673Written as LCL161How we know
- LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisCompletedPhase 2M.D. Anderson Cancer CenterNCT02098161Written as Smac Mimetic LCL161How we know
- A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedPhase 1Novartis PharmaceuticalsNCT02890069Written as LCL161How we know
- Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple MyelomaCompletedPhase 1Novartis PharmaceuticalsNCT03111992Written as LCL161How we know
- A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01240655Written as LCL161How we know
- Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01968915Written as LCL161How we know
- SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 2Mayo ClinicNCT01955434Written as Smac Mimetic LCL161How we know
- A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast CancerCompletedPhase 2Novartis PharmaceuticalsNCT01617668Written as LCL161How we know
- Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic CancerStatus unknownPhase 1US Oncology ResearchNCT01934634Written as LCL161How we know
- Safety and Efficacy of LCL161 in Patients With Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01098838Written as LCL161How we know
Codes
What other systems call LCL161 · ClinicalTrials.gg INT006121
- NCI Thesaurus C91079Smac Mimetic LCL161One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| NCI Thesaurus | C91079 | Smac Mimetic LCL161 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.